APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antiasthmatic Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antiasthmatic Drug Market Outlook and Growth Opportunities 2026

Report ID 17396561042 January 2026200 pages

Choose your research edition.

Industry ResearchAntiasthmatic Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiasthmatic Drug Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Antiasthmatic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiasthmatic Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiasthmatic Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Antiasthmatic Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antiasthmatic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antiasthmatic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiasthmatic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antiasthmatic Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antiasthmatic Drug market include Ruiyang Pharmaceutical Co., Ltd, Novartis AG, Roche, Lunan Pharmaceutical Group Co., Ltd, Kaifeng Kangnuo Pharmaceutical Co., Ltd, GlaxoSmithKline, Fuhe Group, Chengdu Huayu Pharmaceutical Co., Ltd and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antiasthmatic Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antiasthmatic Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antiasthmatic Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antiasthmatic Drug market.

Antiasthmatic Drug Segment by Company

Ruiyang Pharmaceutical Co., Ltd

Novartis AG

Roche

Lunan Pharmaceutical Group Co., Ltd

Kaifeng Kangnuo Pharmaceutical Co., Ltd

GlaxoSmithKline

Fuhe Group

Chengdu Huayu Pharmaceutical Co., Ltd

AstraZeneca

Teva Pharmaceutical Industries Ltd

Mundipharma Pharmaceuticals Ltd.

MSD

Kyorin Pharmaceutical Co.,Ltd.

Kissei Pharmaceutical Co.Ltd.

Daiichi Sankyo Company Limited

Covis Pharmaceutical Inc

Chiesi GmbH

Boehringer Ingelheim Pharma GmbH&Co.KG

Akorn Pharmaceutical Co.Ltd.

ABC Farmaceutici Spa

Antiasthmatic Drug Segment by Type

Anti-allergic Antiasthmatic

Anti-inflammatory Antiasthmatic

Bronchodilators

Antiasthmatic Drug Segment by Application

Hospital

Clinic

Other

Antiasthmatic Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antiasthmatic Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antiasthmatic Drug key companies, revenue, market share, and recent developments.

3. To split the Antiasthmatic Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antiasthmatic Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antiasthmatic Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Antiasthmatic Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiasthmatic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiasthmatic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiasthmatic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antiasthmatic Drug industry.

Chapter 3: Detailed analysis of Antiasthmatic Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antiasthmatic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antiasthmatic Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antiasthmatic Drug Industry Trends Table 2. Antiasthmatic Drug Industry Drivers Table 3. Antiasthmatic Drug Industry Opportunities and Challenges Table 4. Antiasthmatic Drug Industry Restraints Table 5. Global Antiasthmatic Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antiasthmatic Drug Revenue Share by Company (2021-2026) Table 7. Global Antiasthmatic Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antiasthmatic Drug Key Company Manufacturing Base & Headquarters Table 9. Global Antiasthmatic Drug Company, Product Type & Application Table 10. Global Antiasthmatic Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antiasthmatic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Anti-allergic Antiasthmatic Table 15. Significant Companies of Anti-inflammatory Antiasthmatic Table 16. Significant Companies of Bronchodilators Table 17. Global Antiasthmatic Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Antiasthmatic Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Antiasthmatic Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Antiasthmatic Drug Sales Value Share by Type (2021-2026) Table 21. Global Antiasthmatic Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Clinic Table 24. Significant Companies of Other Table 25. Global Antiasthmatic Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antiasthmatic Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Antiasthmatic Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Antiasthmatic Drug Sales Value Share by Application (2021-2026) Table 29. Global Antiasthmatic Drug Sales Value Share by Application (2027-2032) Table 30. Global Antiasthmatic Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antiasthmatic Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Antiasthmatic Drug Sales Value Share by Region (2021-2026) Table 33. Global Antiasthmatic Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Antiasthmatic Drug Sales Value Share by Region (2027-2032) Table 35. Global Antiasthmatic Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Antiasthmatic Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Antiasthmatic Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Antiasthmatic Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Antiasthmatic Drug Sales Value Market Share by Country (2027-2032) Table 40. Ruiyang Pharmaceutical Co., Ltd Company Information Table 41. Ruiyang Pharmaceutical Co., Ltd Business Overview Table 42. Ruiyang Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Ruiyang Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio Table 44. Ruiyang Pharmaceutical Co., Ltd Recent Development Table 45. Novartis AG Company Information Table 46. Novartis AG Business Overview Table 47. Novartis AG Antiasthmatic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novartis AG Antiasthmatic Drug Product Portfolio Table 49. Novartis AG Recent Development Table 50. Roche Company Information Table 51. Roche Business Overview Table 52. Roche Antiasthmatic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Roche Antiasthmatic Drug Product Portfolio Table 54. Roche Recent Development Table 55. Lunan Pharmaceutical Group Co., Ltd Company Information Table 56. Lunan Pharmaceutical Group Co., Ltd Business Overview Table 57. Lunan Pharmaceutical Group Co., Ltd Antiasthmatic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Lunan Pharmaceutical Group Co., Ltd Antiasthmatic Drug Product Portfolio Table 59. Lunan Pharmaceutical Group Co., Ltd Recent Development Table 60. Kaifeng Kangnuo Pharmaceutical Co., Ltd Company Information Table 61. Kaifeng Kangnuo Pharmaceutical Co., Ltd Business Overview Table 62. Kaifeng Kangnuo Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Kaifeng Kangnuo Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio Table 64. Kaifeng Kangnuo Pharmaceutical Co., Ltd Recent Development Table 65. GlaxoSmithKline Company Information Table 66. GlaxoSmithKline Business Overview Table 67. GlaxoSmithKline Antiasthmatic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. GlaxoSmithKline Antiasthmatic Drug Product Portfolio Table 69. GlaxoSmithKline Recent Development Table 70. Fuhe Group Company Information Table 71. Fuhe Group Business Overview Table 72. Fuhe Group Antiasthmatic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Fuhe Group Antiasthmatic Drug Product Portfolio Table 74. Fuhe Group Recent Development Table 75. Chengdu Huayu Pharmaceutical Co., Ltd Company Information Table 76. Chengdu Huayu Pharmaceutical Co., Ltd Business Overview Table 77. Chengdu Huayu Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Chengdu Huayu Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio Table 79. Chengdu Huayu Pharmaceutical Co., Ltd Recent Development Table 80. AstraZeneca Company Information Table 81. AstraZeneca Business Overview Table 82. AstraZeneca Antiasthmatic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. AstraZeneca Antiasthmatic Drug Product Portfolio Table 84. AstraZeneca Recent Development Table 85. Teva Pharmaceutical Industries Ltd Company Information Table 86. Teva Pharmaceutical Industries Ltd Business Overview Table 87. Teva Pharmaceutical Industries Ltd Antiasthmatic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Teva Pharmaceutical Industries Ltd Antiasthmatic Drug Product Portfolio Table 89. Teva Pharmaceutical Industries Ltd Recent Development Table 90. Mundipharma Pharmaceuticals Ltd. Company Information Table 91. Mundipharma Pharmaceuticals Ltd. Business Overview Table 92. Mundipharma Pharmaceuticals Ltd. Antiasthmatic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Mundipharma Pharmaceuticals Ltd. Antiasthmatic Drug Product Portfolio Table 94. Mundipharma Pharmaceuticals Ltd. Recent Development Table 95. MSD Company Information Table 96. MSD Business Overview Table 97. MSD Antiasthmatic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. MSD Antiasthmatic Drug Product Portfolio Table 99. MSD Recent Development Table 100. Kyorin Pharmaceutical Co.,Ltd. Company Information Table 101. Kyorin Pharmaceutical Co.,Ltd. Business Overview Table 102. Kyorin Pharmaceutical Co.,Ltd. Antiasthmatic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Kyorin Pharmaceutical Co.,Ltd. Antiasthmatic Drug Product Portfolio Table 104. Kyorin Pharmaceutical Co.,Ltd. Recent Development Table 105. Kissei Pharmaceutical Co.Ltd. Company Information Table 106. Kissei Pharmaceutical Co.Ltd. Business Overview Table 107. Kissei Pharmaceutical Co.Ltd. Antiasthmatic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Kissei Pharmaceutical Co.Ltd. Antiasthmatic Drug Product Portfolio Table 109. Kissei Pharmaceutical Co.Ltd. Recent Development Table 110. Daiichi Sankyo Company Limited Company Information Table 111. Daiichi Sankyo Company Limited Business Overview Table 112. Daiichi Sankyo Company Limited Antiasthmatic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Daiichi Sankyo Company Limited Antiasthmatic Drug Product Portfolio Table 114. Daiichi Sankyo Company Limited Recent Development Table 115. Covis Pharmaceutical Inc Company Information Table 116. Covis Pharmaceutical Inc Business Overview Table 117. Covis Pharmaceutical Inc Antiasthmatic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Covis Pharmaceutical Inc Antiasthmatic Drug Product Portfolio Table 119. Covis Pharmaceutical Inc Recent Development Table 120. Chiesi GmbH Company Information Table 121. Chiesi GmbH Business Overview Table 122. Chiesi GmbH Antiasthmatic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Chiesi GmbH Antiasthmatic Drug Product Portfolio Table 124. Chiesi GmbH Recent Development Table 125. Boehringer Ingelheim Pharma GmbH&Co.KG Company Information Table 126. Boehringer Ingelheim Pharma GmbH&Co.KG Business Overview Table 127. Boehringer Ingelheim Pharma GmbH&Co.KG Antiasthmatic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Boehringer Ingelheim Pharma GmbH&Co.KG Antiasthmatic Drug Product Portfolio Table 129. Boehringer Ingelheim Pharma GmbH&Co.KG Recent Development Table 130. Akorn Pharmaceutical Co.Ltd. Company Information Table 131. Akorn Pharmaceutical Co.Ltd. Business Overview Table 132. Akorn Pharmaceutical Co.Ltd. Antiasthmatic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Akorn Pharmaceutical Co.Ltd. Antiasthmatic Drug Product Portfolio Table 134. Akorn Pharmaceutical Co.Ltd. Recent Development Table 135. ABC Farmaceutici Spa Company Information Table 136. ABC Farmaceutici Spa Business Overview Table 137. ABC Farmaceutici Spa Antiasthmatic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. ABC Farmaceutici Spa Antiasthmatic Drug Product Portfolio Table 139. ABC Farmaceutici Spa Recent Development Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Antiasthmatic Drug Product Image Figure 2. Global Antiasthmatic Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiasthmatic Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Antiasthmatic Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Anti-allergic Antiasthmatic Image Figure 8. Anti-inflammatory Antiasthmatic Image Figure 9. Bronchodilators Image Figure 10. Global Antiasthmatic Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Antiasthmatic Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Antiasthmatic Drug Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Other Image Figure 16. Global Antiasthmatic Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antiasthmatic Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Antiasthmatic Drug Sales Value Share by Application (2021-2032) Figure 19. Global Antiasthmatic Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Antiasthmatic Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Antiasthmatic Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Antiasthmatic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Antiasthmatic Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Antiasthmatic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Antiasthmatic Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Antiasthmatic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Antiasthmatic Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Antiasthmatic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Antiasthmatic Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Antiasthmatic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Antiasthmatic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-allergic Antiasthmatic
  • Anti-inflammatory Antiasthmatic
  • Bronchodilators
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Ruiyang Pharmaceutical Co., Ltd
  • Novartis AG
  • Roche
  • Lunan Pharmaceutical Group Co., Ltd
  • Kaifeng Kangnuo Pharmaceutical Co., Ltd
  • GlaxoSmithKline
  • Fuhe Group
  • Chengdu Huayu Pharmaceutical Co., Ltd
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd
  • Mundipharma Pharmaceuticals Ltd.
  • MSD
  • Kyorin Pharmaceutical Co.,Ltd.
  • Kissei Pharmaceutical Co.Ltd.
  • Daiichi Sankyo Company Limited
  • Covis Pharmaceutical Inc
  • Chiesi GmbH
  • Boehringer Ingelheim Pharma GmbH&Co.KG
  • Akorn Pharmaceutical Co.Ltd.
  • ABC Farmaceutici Spa

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antiasthmatic Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antiasthmatic Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antiasthmatic Drug Market Dynamics
  1. 2.1 Antiasthmatic Drug Industry Trends
  2. 2.2 Antiasthmatic Drug Industry Drivers
  3. 2.3 Antiasthmatic Drug Industry Opportunities and Challenges
  4. 2.4 Antiasthmatic Drug Industry Restraints
3 Antiasthmatic Drug Market by Company
  1. 3.1 Global Antiasthmatic Drug Company Revenue Ranking in 2025
  2. 3.2 Global Antiasthmatic Drug Revenue by Company (2021-2026)
  3. 3.3 Global Antiasthmatic Drug Company Ranking (2024-2026)
  4. 3.4 Global Antiasthmatic Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Antiasthmatic Drug Company Product Type and Application
  6. 3.6 Global Antiasthmatic Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antiasthmatic Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antiasthmatic Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antiasthmatic Drug Market by Type
  1. 4.1 Antiasthmatic Drug Type Introduction
  2. 4.1.1 Anti-allergic Antiasthmatic
  3. 4.1.2 Anti-inflammatory Antiasthmatic
  4. 4.1.3 Bronchodilators
  5. 4.2 Global Antiasthmatic Drug Sales Value by Type
  6. 4.2.1 Global Antiasthmatic Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antiasthmatic Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Antiasthmatic Drug Sales Value Share by Type (2021-2032)
5 Antiasthmatic Drug Market by Application
  1. 5.1 Antiasthmatic Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Antiasthmatic Drug Sales Value by Application
  6. 5.2.1 Global Antiasthmatic Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antiasthmatic Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Antiasthmatic Drug Sales Value Share by Application (2021-2032)
6 Antiasthmatic Drug Regional Value Analysis
  1. 6.1 Global Antiasthmatic Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antiasthmatic Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antiasthmatic Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antiasthmatic Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antiasthmatic Drug Sales Value (2021-2032)
  7. 6.3.2 North America Antiasthmatic Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antiasthmatic Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Antiasthmatic Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antiasthmatic Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antiasthmatic Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antiasthmatic Drug Sales Value (2021-2032)
  16. 6.6.2 South America Antiasthmatic Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antiasthmatic Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antiasthmatic Drug Sales Value Share by Country, 2025 VS 2032
7 Antiasthmatic Drug Country-level Value Analysis
  1. 7.1 Global Antiasthmatic Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antiasthmatic Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antiasthmatic Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antiasthmatic Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antiasthmatic Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antiasthmatic Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antiasthmatic Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Ruiyang Pharmaceutical Co., Ltd
  2. 8.1.1 Ruiyang Pharmaceutical Co., Ltd Company Information
  3. 8.1.2 Ruiyang Pharmaceutical Co., Ltd Business Overview
  4. 8.1.3 Ruiyang Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Ruiyang Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio
  6. 8.1.5 Ruiyang Pharmaceutical Co., Ltd Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Antiasthmatic Drug Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Antiasthmatic Drug Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Lunan Pharmaceutical Group Co., Ltd
  20. 8.4.1 Lunan Pharmaceutical Group Co., Ltd Company Information
  21. 8.4.2 Lunan Pharmaceutical Group Co., Ltd Business Overview
  22. 8.4.3 Lunan Pharmaceutical Group Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lunan Pharmaceutical Group Co., Ltd Antiasthmatic Drug Product Portfolio
  24. 8.4.5 Lunan Pharmaceutical Group Co., Ltd Recent Developments
  25. 8.5 Kaifeng Kangnuo Pharmaceutical Co., Ltd
  26. 8.5.1 Kaifeng Kangnuo Pharmaceutical Co., Ltd Company Information
  27. 8.5.2 Kaifeng Kangnuo Pharmaceutical Co., Ltd Business Overview
  28. 8.5.3 Kaifeng Kangnuo Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Kaifeng Kangnuo Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio
  30. 8.5.5 Kaifeng Kangnuo Pharmaceutical Co., Ltd Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Antiasthmatic Drug Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Fuhe Group
  38. 8.7.1 Fuhe Group Company Information
  39. 8.7.2 Fuhe Group Business Overview
  40. 8.7.3 Fuhe Group Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Fuhe Group Antiasthmatic Drug Product Portfolio
  42. 8.7.5 Fuhe Group Recent Developments
  43. 8.8 Chengdu Huayu Pharmaceutical Co., Ltd
  44. 8.8.1 Chengdu Huayu Pharmaceutical Co., Ltd Company Information
  45. 8.8.2 Chengdu Huayu Pharmaceutical Co., Ltd Business Overview
  46. 8.8.3 Chengdu Huayu Pharmaceutical Co., Ltd Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Chengdu Huayu Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio
  48. 8.8.5 Chengdu Huayu Pharmaceutical Co., Ltd Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Antiasthmatic Drug Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Teva Pharmaceutical Industries Ltd
  56. 8.10.1 Teva Pharmaceutical Industries Ltd Company Information
  57. 8.10.2 Teva Pharmaceutical Industries Ltd Business Overview
  58. 8.10.3 Teva Pharmaceutical Industries Ltd Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceutical Industries Ltd Antiasthmatic Drug Product Portfolio
  60. 8.10.5 Teva Pharmaceutical Industries Ltd Recent Developments
  61. 8.11 Mundipharma Pharmaceuticals Ltd.
  62. 8.11.1 Mundipharma Pharmaceuticals Ltd. Company Information
  63. 8.11.2 Mundipharma Pharmaceuticals Ltd. Business Overview
  64. 8.11.3 Mundipharma Pharmaceuticals Ltd. Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Mundipharma Pharmaceuticals Ltd. Antiasthmatic Drug Product Portfolio
  66. 8.11.5 Mundipharma Pharmaceuticals Ltd. Recent Developments
  67. 8.12 MSD
  68. 8.12.1 MSD Company Information
  69. 8.12.2 MSD Business Overview
  70. 8.12.3 MSD Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 MSD Antiasthmatic Drug Product Portfolio
  72. 8.12.5 MSD Recent Developments
  73. 8.13 Kyorin Pharmaceutical Co.,Ltd.
  74. 8.13.1 Kyorin Pharmaceutical Co.,Ltd. Company Information
  75. 8.13.2 Kyorin Pharmaceutical Co.,Ltd. Business Overview
  76. 8.13.3 Kyorin Pharmaceutical Co.,Ltd. Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Kyorin Pharmaceutical Co.,Ltd. Antiasthmatic Drug Product Portfolio
  78. 8.13.5 Kyorin Pharmaceutical Co.,Ltd. Recent Developments
  79. 8.14 Kissei Pharmaceutical Co.Ltd.
  80. 8.14.1 Kissei Pharmaceutical Co.Ltd. Company Information
  81. 8.14.2 Kissei Pharmaceutical Co.Ltd. Business Overview
  82. 8.14.3 Kissei Pharmaceutical Co.Ltd. Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Kissei Pharmaceutical Co.Ltd. Antiasthmatic Drug Product Portfolio
  84. 8.14.5 Kissei Pharmaceutical Co.Ltd. Recent Developments
  85. 8.15 Daiichi Sankyo Company Limited
  86. 8.15.1 Daiichi Sankyo Company Limited Company Information
  87. 8.15.2 Daiichi Sankyo Company Limited Business Overview
  88. 8.15.3 Daiichi Sankyo Company Limited Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Daiichi Sankyo Company Limited Antiasthmatic Drug Product Portfolio
  90. 8.15.5 Daiichi Sankyo Company Limited Recent Developments
  91. 8.16 Covis Pharmaceutical Inc
  92. 8.16.1 Covis Pharmaceutical Inc Company Information
  93. 8.16.2 Covis Pharmaceutical Inc Business Overview
  94. 8.16.3 Covis Pharmaceutical Inc Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Covis Pharmaceutical Inc Antiasthmatic Drug Product Portfolio
  96. 8.16.5 Covis Pharmaceutical Inc Recent Developments
  97. 8.17 Chiesi GmbH
  98. 8.17.1 Chiesi GmbH Company Information
  99. 8.17.2 Chiesi GmbH Business Overview
  100. 8.17.3 Chiesi GmbH Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Chiesi GmbH Antiasthmatic Drug Product Portfolio
  102. 8.17.5 Chiesi GmbH Recent Developments
  103. 8.18 Boehringer Ingelheim Pharma GmbH&Co.KG
  104. 8.18.1 Boehringer Ingelheim Pharma GmbH&Co.KG Company Information
  105. 8.18.2 Boehringer Ingelheim Pharma GmbH&Co.KG Business Overview
  106. 8.18.3 Boehringer Ingelheim Pharma GmbH&Co.KG Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim Pharma GmbH&Co.KG Antiasthmatic Drug Product Portfolio
  108. 8.18.5 Boehringer Ingelheim Pharma GmbH&Co.KG Recent Developments
  109. 8.19 Akorn Pharmaceutical Co.Ltd.
  110. 8.19.1 Akorn Pharmaceutical Co.Ltd. Company Information
  111. 8.19.2 Akorn Pharmaceutical Co.Ltd. Business Overview
  112. 8.19.3 Akorn Pharmaceutical Co.Ltd. Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Akorn Pharmaceutical Co.Ltd. Antiasthmatic Drug Product Portfolio
  114. 8.19.5 Akorn Pharmaceutical Co.Ltd. Recent Developments
  115. 8.20 ABC Farmaceutici Spa
  116. 8.20.1 ABC Farmaceutici Spa Company Information
  117. 8.20.2 ABC Farmaceutici Spa Business Overview
  118. 8.20.3 ABC Farmaceutici Spa Antiasthmatic Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 ABC Farmaceutici Spa Antiasthmatic Drug Product Portfolio
  120. 8.20.5 ABC Farmaceutici Spa Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst